FREE delivery to all EXCLUSIVE BOOKS stores nationwide. FREE delivery to your door on all orders over R450. Excludes all international deliveries.

Acute Myelogenous Leukemia

Lalitha Nagarajan
    Product form
      FORMAT: Hardback

      R 2,015.00 Price and availability exclusive to website

      YOU COULD EARN 2,015 FUTURE RETAIL DISCOUNTS.
      ESTIMATED DELIVERY: Approx. 20 - 30 Business Days
      BUY NOW PAY LATER
      From R 335.83 per month!
      3x monthly payments of R 671.66 with
      4x fortnightly payments of R 503.75 with
      Acute myelogenous leukemia (AML), is the most common form of leukemia in adults. AML is a deadly form of malignancy, the prognosis for which has not improved in the last two decades. More importantly, it is a malignancy that is seen in older adults, therefore the number of cases is likely to rise as the population ages. Over the past 15 years, genetic mechanisms underlying AML have begun to unfold. Additional research in this area has helped identify key components and characteristics. Consequently, targeted therapy of AML is receiving much attention. It is the hope of researchers that as with chronic myelogenous leukemia (CML), and the drug, Gleevec, a targeted therapy for AML will be discovered.
      Format: CONTRIBUTORS: Lalitha Nagarajan EAN: 9780387692579 COUNTRY: United States PAGES: WEIGHT: 659 g HEIGHT: 0 cm
      PUBLISHED BY: Springer-Verlag New York Inc. DATE PUBLISHED: 2009-11-18 CITY: GENRE: MEDICAL / Hematology, MEDICAL / Oncology / General, SCIENCE / System Theory WIDTH: 0 cm SPINE:

      Book Themes:

      Cybernetics and systems theory, Oncology, Haematology

      Customer Reviews

      Be the first to write a review
      0%
      (0)
      0%
      (0)
      0%
      (0)
      0%
      (0)
      0%
      (0)
      Lalitha Nagarajan is an Associate Professor, Department of Molecular Genetics, The University of Texas, M.D. Anderson Cancer Center, Houston, Texas. 
      Acute myelogenous leukemia (AML), is the most common form of leukemia in adults. AML is a deadly form of malignancy, the prognosis for which has not improved in the last two decades. More importantly, it is a malignancy that is seen in older adults, therefore the number of cases is likely to rise as the population ages. Over the past 15 years, genetic mechanisms underlying AML have begun to unfold. Additional research in this area has helped identify key components and characteristics. Consequently, targeted therapy of AML is receiving much attention. It is the hope of researchers that as with chronic myelogenous leukemia (CML), and the drug, Gleevec, a targeted therapy for AML will be discovered.
      Format: CONTRIBUTORS: Lalitha Nagarajan EAN: 9780387692579 COUNTRY: United States PAGES: WEIGHT: 659 g HEIGHT: 0 cm
      PUBLISHED BY: Springer-Verlag New York Inc. DATE PUBLISHED: 2009-11-18 CITY: GENRE: MEDICAL / Hematology, MEDICAL / Oncology / General, SCIENCE / System Theory WIDTH: 0 cm SPINE:

      Book Themes:

      Cybernetics and systems theory, Oncology, Haematology

      Customer Reviews

      Be the first to write a review
      0%
      (0)
      0%
      (0)
      0%
      (0)
      0%
      (0)
      0%
      (0)
      Lalitha Nagarajan is an Associate Professor, Department of Molecular Genetics, The University of Texas, M.D. Anderson Cancer Center, Houston, Texas. 

      Recently viewed products

      Login

      Forgot your password?

      Don't have an account yet?
      Create account